Mustang Bio, Inc. (MBIO)
0.5412
0.00 (0.00%)
USD |
NASDAQ |
Sep 08, 16:00
Mustang Bio Total Assets (Quarterly) : 15.61M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 15.61M |
| March 31, 2026 | 16.58M |
| December 31, 2025 | 17.59M |
| September 30, 2025 | 19.36M |
| June 30, 2025 | 13.05M |
| March 31, 2025 | 14.91M |
| December 31, 2024 | 9.308M |
| September 30, 2024 | 7.193M |
| June 30, 2024 | 8.519M |
| March 31, 2024 | 14.59M |
| December 31, 2023 | 17.74M |
| September 30, 2023 | 20.57M |
| June 30, 2023 | 29.09M |
| March 31, 2023 | 73.61M |
| December 31, 2022 | 92.42M |
| September 30, 2022 | 108.84M |
| June 30, 2022 | 121.90M |
| March 31, 2022 | 136.96M |
| December 31, 2021 | 125.17M |
| September 30, 2021 | 134.71M |
| June 30, 2021 | 143.21M |
| Date | Value |
|---|---|
| March 31, 2021 | 141.82M |
| December 31, 2020 | 109.90M |
| September 30, 2020 | 86.07M |
| June 30, 2020 | 96.83M |
| March 31, 2020 | 68.56M |
| December 31, 2019 | 73.44M |
| September 30, 2019 | 83.84M |
| June 30, 2019 | 92.62M |
| March 31, 2019 | 50.48M |
| December 31, 2018 | 42.75M |
| September 30, 2018 | 49.51M |
| June 30, 2018 | 55.68M |
| March 31, 2018 | 61.09M |
| December 31, 2017 | 63.49M |
| September 30, 2017 | 67.88M |
| June 30, 2017 | 73.84M |
| March 31, 2017 | 75.02M |
| December 31, 2016 | 27.50M |
| September 30, 2016 | 11.12M |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.743B |
| Alnylam Pharmaceuticals, Inc. | 5.559B |
| Anika Therapeutics, Inc. | 183.47M |
| Savara, Inc. | 192.14M |
| Vericel Corp. | 502.87M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 8.068M |
| Shareholders Equity (Quarterly) | 7.545M |
| Current Ratio | 1.972 |